Looking back at 2020 outlook by John D. Vandermosten Summary
ProMIS has continued to advance its preclinical programs and enter into diagnosting testing collaborations to detect both coronavirus and Alzheimer s Disease. Parallel with these endeavors is the continued interaction with the scientific, investment and corporate community to garner KOL support, financing and partnerships. Management has refined its message highlighting the need to focus on the toxic forms of misfolded proteins that are the root cause of neurodegenerative disease and the importance of biomarkers that can rapidly and inexpensively demonstrate efficacy. We continue to be impressed with ProMIS discovery platforms and their ability to identify unique features of toxic misfolded proteins and their ability to be repurposed to identify targets for the coronavirus. We believe that a pharmaceutical partner deal or large investment will allow the company to advance its candidates into the clinic.
ProMIS represents an attractive opportunity to gain exposure to a disorder with no other approved disease modifying therapies. There are almost six million people in the US and over 30 million people outside of the US suffering from AD. Additionally, there is a larger population with mild cognitive impairment (MCI) and pre- Alzheimer s which may benefit even more from toxic oligomer sequestering therapy. The path forward is relatively clear with other assets setting the precedent for trial design and potentially accelerated approaches using biomarkers suggested by regulatory agencies. There is also substantial opportunity for drug development in PD, MSA and ALS.
Due to the uncertain environment regarding to aducanumab, the investment community is waiting to invest new money in A programs. We expect to see a response by the FDA to Biogen s drug by March of next year, which may bring attention back to the A space.
ProMIS has a number of recent and upcoming milestones related to development of its pipeline which we
summarize below.
We continue to believe in the potential of PMN310 and the other
candidates in development and the tremendous opportunity in AD and other neurodegenerative diseases due to the